CAMBRIDGE, Mass. - Sarepta Therapeutics (NASDAQ: SRPT) reported fourth quarter earnings that beat analyst expectations, but the stock fell 4.6% as investors focused on rising expenses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback